Republican clinical oncological dispencery
Ufa, Bashkortostan Republic, 450054, Russia
NCT Number: NCT05745909
The purpose of this study is to determine which stoma creation technique is preferable after low anterior resection of the rectum.
Looking for future studies?
Notify Me18 year–79 year
All sexes
Interventional
Not applicable
Ufa, Bashkortostan Republic, 450054, Russia
The investigators enroll patients with a histologically confirmed diagnosis of primary rectal cancer with or without prior chemoradiotherapy who were hospitalized at the Ufa Republican Clinical Oncology Center from February 2023 to February 2024.
All patients undergo planned laparoscopic or open low-anterior resection of the rectum with total mesorectal excision. Patients are randomized into 2 groups in a 1:1 ratio. In the first group, a loop transverse colostomy is created, and in the second group, a loop ileostomy is created. The stoma exit sites are marked in advance the day before the surgery. The bowels are prepared by mechanical means (a polyethylene glycol-based laxative with a cleansing enema) according to a standard procedure before the surgery. Standardized stoma creation techniques are used. The resected parts are collected through a separate access. Patients are followed up for 60 days after surgery.
The sample size should be 124 patients to reach statistical significance (α = 0.05, study power 80%, confidence interval (CI) = 95%.). Considering possible losses during the study, the number of patients was increased to 130.
The investigators hypothesis is that the loop ileostomy group has a 20% higher incidence of stoma dysfunction but a 20% lower incidence of SSI (stoma site infections) compared to the loop colostomy group.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The loop transverse colostomy is matured without torsion using a plastic retainer. The stoma protrudes 2-3 cm. The loop of the transverse colon is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
The loop ileostomy is matured 25-30 cm from the ileocecal angle without torsion and without a retainer, so that stoma protrudes 2-3 cm. The loop of the ileum is sutured with interrupted sutures using an absorbable 3/0 polyglactin suture without piercing the intestinal wall. The intestinal lumen is opened through a transverse incision on the antimesenteric border.
Time frame: 60 days after surgery
incidence of stoma site infections
Time frame: 60 days after surgery
incidence of stoma dysfunction
Time frame: within the first 60 days after surgery
readmission rate
Time frame: From date of surgery until the date of discharge, assessed up to 60 days
the number of days from surgery to discharge
Time frame: within the first 6 months days after surgery
the number of days from surgery to stoma closure
Time frame: 60 days after surgery
the occurrence of anything other than serous-hemorrhagic contents in the colostomy bag
Time frame: within the first 2 months days after surgery
the number of days from surgery to hospitalization for first chemotherapy
Time frame: within the first 60 days after surgery
estimated using EORTC QLQ-CR29
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan
Other
Randomized Single Center Clinical Trial Comparing Loop Ileostomy Versus Loop Transverse Colostomy in Patients After Major Anterior Resections
Acronym: LIVELOC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04075305
Bladder Cancer, Bladder Neoplasm
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT04006951
Colonic Diseases, Colorectal Neoplasms
Montpellier, France
View Trial DetailsNCT05496491
Colorectal Neoplasms, Digestive System Diseases
Larissa, Greece
View Trial DetailsNCT06204497
Anastomotic Leak, Colorectal Neoplasms
Beijing, Beijing Municipality, China
View Trial Details